Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2023-01-30 00:00:00 ET · period of report 2023-01-27 · accession 0001209191-23-005471 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-30 | 2023-01-27 | CBIO | Koenig Scott | Dir | M - OptEx | $2.55 | +10.5K | 15.8K | +200% | +$26.8K |
| D | 2023-01-30 | 2023-01-27 | CBIO | Koenig Scott | Dir | M - OptEx | $0.00 | -10.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-27 | M | A | 10,500 | $2.55 | 15,750 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-01-27 | M | D | 10,500 | $0.00 | 0 | D | $2.55 · — to 2031-05-17 | 10,500 Common Stock | (F1) The shares underlying this option vested on May 18, 2022 and are fully exercisable. |